WO1994014407A1 - Oral compositions containing antiplaque, anticalculus agents - Google Patents

Oral compositions containing antiplaque, anticalculus agents Download PDF

Info

Publication number
WO1994014407A1
WO1994014407A1 PCT/US1993/011787 US9311787W WO9414407A1 WO 1994014407 A1 WO1994014407 A1 WO 1994014407A1 US 9311787 W US9311787 W US 9311787W WO 9414407 A1 WO9414407 A1 WO 9414407A1
Authority
WO
WIPO (PCT)
Prior art keywords
zinc
compositions
ions
composition
oral
Prior art date
Application number
PCT/US1993/011787
Other languages
French (fr)
Inventor
Ronald Earl Montgomery
Joseph Wasyl Pyrz
Margaret Mary Coyle-Rees
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Priority to JP6515185A priority Critical patent/JPH08505843A/en
Priority to BR9307688-6A priority patent/BR9307688A/en
Priority to AU57400/94A priority patent/AU5740094A/en
Priority to EP94903459A priority patent/EP0675706A1/en
Publication of WO1994014407A1 publication Critical patent/WO1994014407A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24Phosphorous; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365Hydroxycarboxylic acids; Ketocarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Definitions

  • the subject invention relates to oral compositions, such as dentifrices and oral solutions, for the treatment or prevention of dental plaque, calculus and gingivitis, and mouth malodor.
  • the mouth is a habitat for microbial growth and colonization.
  • the gums, lips, oral mucosa (cheek), palate, tongue and teeth provide surfaces for the colonization and accumulation of bacteria.
  • Teeth are unique in the oral cavity because they have hard, non-shedding surfaces where bacteria and their products (dental plaque) can significantly accumulate, especially in approximal areas and along the gingival crevice.
  • Dental plaque is a rough sticky film on the teeth that is made up of saliva, bacteria and food particles which adheres tenaciously to teeth at points of irregularity or discontinuity.
  • salivary mucins consisting primarily of proteins
  • Various oral bacteria colonize the mucins and multiply, forming a layer of plaque.
  • Carbohydrate food debris adheres to the mucins and is digested by some types of plaque- causing bacteria. The digestion both produces by-products which add to the plaque, and produces acid which erodes tooth enamel.
  • the bacterial by-products produced in the oral cavity also include foul smelling gases which can result in malodor of the oral cavity.
  • the oral bacteria in dental plaque includes many gram positive and gram negative microorganisms embedded in an extracellular matrix of insoluble polysaccharides, firmly attached to teeth and other oral surfaces.
  • the colonization of bacteria to form dental plaque follows an ecological pattern where a few pioneer aerobic species, mostly gram-positive streptococci, colonize enamel surfaces. The plaque then progresses through stages of increasing microbial complexity. Mature plaques, often found in protected regions of the teeth, such as cracks, approximal regions and in the gingival crevice, typically contain anaerobes. Saliva and crevicular fluid are a source of nutrients for the dental plaque. Local conditions affect the metabolic activity and composition of dental plaque.
  • plaque may become embedded with mineral salts, containing calcium and phosphate, to form a hard crusty deposit, calculus or tartar, on the teeth.
  • Calculus may be white or yellowish in color or may be stained or discolored by extraneous agents. Calculus tends to be more unsightly than plaque and much more difficult to remove from the teeth.
  • the toxins in plaque and calculus can irritate the gingival tissues surrounding the coated teeth, causing inflammation and destruction of the gums which can lead to other complications.
  • Zinc is an anticalculus agent; however, compositions containing zinc generally taste astringent and unknowingly bitter. Like the chemical and biological activities, the negative aesthetics of the zinc cation are dose dependent: higher concentrations of zinc exhibit poorer aesthetics; therefore, increasing the concentration of free zinc tends to increase efficacy at the expense of aesthetics. This coupled behavior between efficacy and aesthetics has limited the utility of zinc in oral compositions. Pyrophosphate is also an anticalculus agent and, likewise, has an unpleasant taste which worsens with increased pyrophosphate concentration. By carefully formulating zinc and pyrophosphate-containing compositions, applicants have surprisingly found that the level of zinc in an oral composition can be increased, thus increasing the corresponding anticalculus effect, without greatly increasing the negative aesthetics of the composition.
  • compositions for impeding calculus formation in the oral cavity It is an object of the subject invention to provide compositions for impeding calculus formation in the oral cavity. It is also an object of the subject invention to provide compositions for impeding dental plaque formation in the oral cavity. It is a further object of the subject invention to provide methods for impeding calculus formation in the oral cavity.
  • This invention involves a composition for treating or preventing dental plaque, calculus and gingivitis, or malodor of the oral cavity, comprising:
  • This invention also involves methods for treating or preventing dental plaque, calculus and gingivitis, or malodor of the oral cavity, comprising administering to the oral cavity of a human or other animal such a composition.
  • the subject invention provides compositions effective against dental plaque formation, calculus formation, gingivitis, and mouth malodor.
  • “Pharmaceutically-acceptable topical oral carrier” denotes a carrier for the active compounds of the subject invention (hereinafter “Actives”) comprising solid or liquid filler diluents suitable for use in contact with the oral tissues of humans and lower animals without undue toxicity, incompatibility, instability, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio.
  • Actives active compounds of the subject invention
  • Such topical oral carrier when combined with Actives of the subject invention, results in a composition which is administered topically to the oral cavity.
  • Such compositions are held in the oral cavity for a period of time, and then largely expectorated rather than being swallowed.
  • compositions include mouthwashes, mouth rinses, mouth sprays, dental treatment solutions, toothpastes, dental gels, tooth powders, prophylaxis pastes, lozenges, chewing gums and the like and are more fully described hereinafter. Dentifrices and mouthwashes are the preferred compositions.
  • Polyro refers to pyrophosphate; phosphonate; diphosphonate; and pharmaceutically-acceptable polyphosphates including, but not limited to, linear condensed polyphosphates of the general formula: (P n O(3 n+1 ⁇ )( n+2 )"wherein n is an integer from 2 to
  • Free pyro refers to pyro that is not bound or chelated to the transition metal, zinc.
  • Free zinc refers to hydrated zinc cationic species, such as Zn(H2 ⁇ )6 2+ . As used herein, percentages listed are weight percentage of composition unless otherwise specified.
  • the amounts of pyro and citrate are expressed in terms of a ratio to the amount of zinc in the oral composition.
  • the amount of citrate relative to zinc is at least one when the molar amount of zinc is one (i.e. the molar, ratio of zincxitrate is at most about 1:1); and the amount of pyro relative to zinc is at least one when the molar amount of zinc is one (i.e. the molar ratio of zinc:pyro is at most about 1:1).
  • the zincxitrate ratio is from about 1:1 to about 1:20; more preferably from about 1:1 to about 1:4, more still preferably from about 1:1 to about 1:3.
  • a zinc: pyro ratio from about 1:1 to about 1:20 more preferably from about 1:1 to about 1:8, more preferably still from about 1:1.5 to about 1:6.
  • a zincxitrate.pyro ratio wherein the sum of the molar ratio amounts of citrate ions and pyro ions is from about 2 to about 9, more preferably from about 3 to about 9, when the ratio amount of zinc is 1.
  • the amount of zinc suitable for the purposes of the subject invention is from about 0.005% to about 5% Zn; more preferably from about 0.03% to about 3% Zn; more preferably still from about 0.05% to about 2% Zn.
  • the preferred amounts of zinc are from about 0.1% to about 2%, more preferably from about 0.25% to about 1%.
  • the preferred amount of zinc is from about 0.005% to about 1%, more preferably from about 0.05% to about 0.5%.
  • the amount of citrate anion suitable for the purposes of the subject invention is from about 0.015% to about 25% citrate.
  • the preferred amounts of citrate anion are from about 0.2 % to about 17%, more preferably from about 0.7% to about 12%, more preferably still from about 1.5% to about 5%.
  • the preferred amount of citrate anion is from about 0.01% to about 12%, more preferably from about 0.1% to about 6%, more preferably still from about 0.15% to about 1 %.
  • the amount of pyro anion suitable for the purposes of the subject invention is from about 0.015% to about 25% pyro.
  • the preferred amounts of pyro ion are from about 0.25% to about 16%, more preferably from about 0.6% to about 11%.
  • the preferred amount of pyro anion is from about 0.01 % to about 11 %, more preferably from about 0.1% to about 5%.
  • Suitable sources of zinc ions include zinc oxides, zinc halides, zinc-strong acid complexes, Zn(N03)2, Zn(CIO_ )2, ZnSO_ , and zinc- organic acids sources such as zinc lactate, tartrate, citrate salts, zinc citrate trihydrate and sodium zinc citrate.
  • Zinc sources that are unacceptable are zinc ethylenediaminetetraacetate (ZnEDTA) and zinc nitrilotriacetate (ZnNTA).
  • Preferred sources of zinc ions include zinc oxide (ZnO) and zinc nitrate; more preferred is ZnO.
  • Suitable sources of citrate ions include zinc citrate; citric acid; alkali metal salts of citric acid, especially sodium citrate and potassium citrate; pharmaceutically acceptable hydrated and dehydrated salts of any of the above; and mixtures of any of the above.
  • Suitable sources of pyro ions are disclosed in U.S. Pat. No.
  • Suitable pyro ion sources include tetrasodium pyrophosphate, sodium acid pyrophosphate (Na2H2P2 >7), tetrapotassium pyrophosphate (K4P2O7); phosphates including, but not limited to, linear condensed polyphosphates of the general an integer from 2 to 21; phosphonates and diphosphonates, such as EHDP (ethane-1-hydroxy-1,1-diphosphonate) and AHP (azacyclo- heptane-2,2-diphosphonic acid); pharmaceutically-acceptable alkali metal salts of pyrophosphates, polyphosphates, phosphonates and diphosphonates; and mixtures of any of the above.
  • EHDP ethane-1-hydroxy-1,1-diphosphonate
  • AHP azacyclo- heptane-2,2-diphosphonic acid
  • Preferred pyro ions are pyrophosphate ions; preferred polyphosphate ions are those of the above formula wherein n is 6, 13, and 21.
  • Preferred alkali metals are sodium and potassium for solubility reasons; mixtures of alkali metal salts are acceptable.
  • the pH of oral compositions of the subject invention is critical but can be varied to some extent.
  • the oral compositions are at a pH of from about 6 to about 9, more preferably from about 6.25 to about 8.75, more preferably still from about 7.5 to about 8.5.
  • the conditions for addition of each component should be optimized such that the pH of the mixture does not drop below formulation pH at any time during mixing the indredients.
  • safe and effective amount as used herein is meant an amount of compound or composition sufficient to induce a significant positive modification in the condition to be treated, but low enough to avoid serious side effects (at a reasonable benefit/risk ratio), within the scope of sound medical judgment.
  • the safe and effective amount of the compound or composition will vary with the particular condition being treated, the age and physical condition of the patient being treated, the severity of the condition, the duration of the treatment, the nature of concurrent therapy, the specific compound or composition employed, the particular pharmaceutically-acceptable carrier utilized, and like factors.
  • compositions of this invention are suitable for administration to the oral cavity of a human or lower animal and are compatible with one another and the other components, especially with the Actives, used in an oral composition of the subject invention.
  • compatible means that the components are capable of being co-mingled with one another, in a manner such that there is no interaction which would substantially reduce the efficacy of the oral composition under ordinary use conditions.
  • Preferred topical, oral carriers provide the desired characteristics for mouthwashes, mouth rinses, mouth sprays, dental treatment solutions, toothpastes, dental gels, toothpowders, prophylaxis pastes, lozenges, chewing gums, and the like.
  • the topical, oral carriers of the subject invention comprise components typically used in such compositions which are well known to a skilled practitioner. Such components include, but are not limited to, anticaries agents, antiplaque agents, anticalculus agents, dental abrasives, surfactants, flavoring agents, sweetening agents, binders, humectants, thickening agents, buffering agents, preservatives, coloring agents and pigments, ethanol and water.
  • Water is an optional component of the topical, oral carriers of the compositions of the subject invention.
  • Water employed in the preparation of the commercially suitable compositions should preferably be of low ion content and free of organic impurities.
  • Water preferably comprises from about 2% to about 99%, more preferably from about 20% to about 95% of the compositions of the subject invention.
  • the compositions preferably comprise from about 2% to about 80%, more preferably from about 30% to about 60%, water, while mouthwashes comprise preferably from about 45% to about 99%, more preferably from about 75% to about 98%, water.
  • Dental abrasives useful in the topical, oral carriers of the compositions of the subject invention include many different materials.
  • the material selected must be one which is compatible with the composition of interest and does not excessively abrade dentin.
  • These include, for example, silicas, including gels and precipitates, calcium carbonate, dicalcium orthophosphate dihydrate, calcium pyrophosphate, tricalcium phosphate, calcium polymeta-phosphate, insoluble sodium polymeta-phosphate, hydrated alumina, • and resinous abrasive materials such as particulate condensation products of urea and formaldehyde, and other materials such as those disclosed by Cooley et al. in U.S. Pat. No. 3,070,510, issued December 25, 1962, incorporated herein by reference. Mixtures of abrasives may also be used.
  • Silica dental abrasives of various types, can provide the unique benefits of exceptional dental cleaning and polishing performance without unduly abrading tooth enamel or dentin. For this reason they are preferred for use herein.
  • the silica abrasive polishing materials useful herein, as well as the other abrasives generally have an average particle size ranging between about 0.1 and 30 microns, preferably between about 5 and 15 microns.
  • the silica abrasive can be precipitated silica or silica gels such as the silica xerogels described in U.S. Pat. No. 3,538,230, issued March 2, 1970 to Pader et al., and in U.S. Pat. No. 3,862,307, issued June 21, 1975 to DiGiulio, both incorporated herein by reference.
  • Preferred precipitated silica materials include those marketed by the J. M. Huber Corporation under the tradename, Zeodent®, particularly the silica carrying the designation Zeodent 119®. These silica abrasives are described in U.S. Pat. No. 4,340,583, Wason, issued July 20, 1982, incorporated herein by reference.
  • abrasives may be used.
  • the amount of abrasive in the compositions described herein ranges from about 6% to about 70%, preferably from about 15% to about 50%, when the dentifrice is a toothpaste. Higher levels, as high as 90%, may be used if the composition is a tooth powder.
  • Flavoring agents can also be added to the oral compositions of the subject invention to make them more palatable. Suitable flavoring agents include menthol, oil of wintergreen, oil of peppermint, oil of spearmint, oil of sassafras, and oil of clove. Flavoring agents are generally included in the subject compositions in amounts of from 0% to about 3%, preferably from about 0.04% to about 2% by weight.
  • Coloring agents may be added to compositions of the subject invention to improve appearance. If present, coloring agents typically are included at levels of from about 0.001 % to about 0.5% by weight. Sweetening agents are also preferred in the compositions of the subject invention to make them more palatable. Sweetening agents which can be used include aspartame, acesulfame, saccharin salts, dextrose, glucose, levulose thaumatin, D-tryptophan, dihydrochalcones, and cyclamate salts. Saccharin salts are preferred. Sweetening agents are generally used in the subject compositions in amounts of from 0% to about 6%, preferably from about 0.005% to about 5% by weight.
  • Oral compositions can also contain a surfactant.
  • Suitable surfactants are those which are reasonably stable and form suds throughout a wide pH range, including nonsoap anionic, nonionic, cationic, zwitterionic and amphoteric organic synthetic detergents, and compatible mixtures thereof. Many of these suitable surfactants are disclosed in U.S. Pat. No. 4,051,234, issued to Gieske et al. on September 27, 1977, and in U.S. Pat. No. 3,959,458 issued to Agricola, Briner, Granger and Widder on May 25, 1976, both of which are incorporated herein by reference.
  • Surfactants are typically present in compositions of the subject invention at a level of from 0% to about 20%, preferably from about 0.1, more preferably from about 1% to about 4% by weight. Surfactants may also be used as solubilizing agents to help retain sparingly soluble components, e.g., some flavoring agents, in solutions. Surfactants suitable for this purpose include polysorbates and poloxamers. Preferred are surfactants which are non-ionic at the formulation pH of the compositions.
  • binders and/or thickening agents are natural gums such as gum karaya, gum arabic, and gum tragacanth; polysaccharide gums such as xanthan gum; and other natural products such as carrageenan; chemically modified natural products such as those based on cellulose esters, that is, carboxyimethylcellulose (CMC), hydroxyethylcellulose (HEC), and hydroxypropylcellulose (HPC); and synthetic binders such as polyvinylpyrrolidone; and water soluble salts of cellulose ethers such as sodium carboxymethyl cellulose and sodium carboxymethyl hydroxyethyl cellulose.
  • CMC carboxyimethylcellulose
  • HEC hydroxyethylcellulose
  • HPC hydroxypropylcellulose
  • synthetic binders such as polyvinylpyrrolidone
  • water soluble salts of cellulose ethers such as sodium carboxymethyl cellulose and sodium carboxymethyl hydroxyethyl cellulose.
  • Carboxyvinyl polymer binders are less desirable, but may be used. Colloidal magnesium aluminum silicate or finely divided silica can be used as part of the thickening agent to further improve texture. Blends and mixtures of the suitable binders may significantly improve the characteristics of compositions made therewith. Preferred binders are chemically modified celluloses such as CMC or HEC; more preferred is HEC. Binders and thickening agents are generally present in the compositions of the subject invention in amounts of from about 0.1% to 10%, preferably from about 0.25% to about 7.5%, more preferably from about 0.5% to about 3.5%.
  • humectant serves to keep toothpaste compositions from hardening upon exposure to air, and to give mouthwash and toothpaste compositions a moist feel to the mouth. Certain humectants can also impart desirable sweetness of flavor to mouthwash and toothpaste compositions.
  • the humectant on a pure humectant basis, generally comprises from 0% to about 70%, preferably from about 2% to about 55%, by weight of the compositions herein.
  • Suitable humectants for use in compositions of the subject invention include edible polyhydric alcohols such as glycerin, sorbitol, xylitol, polyethylene glycol, and propylene glycol, especially sorbitol and glycerin.
  • Opacifiers may also be used in toothpastes of the subject invention to render the toothpaste opaque.
  • Suitable opacifiers include titanium dioxide and some abrasives including, for example, magnesium aluminum silicate.
  • Opacifiers generally comprise from 0% to about 4%, preferably from about 0.5% to about 3% by weight of the compositions herein.
  • compositions of the subject invention are preservatives.
  • the preservatives prevent microbial growth in the compositions. Suitable preservatives include methylparaben, propylparaben, benzoates and ethanol. If the preservative is ethanol, it generally comprises from 0% to about 35% by weight, preferably from about 5% to about 15%, of the compositions herein. Other preservatives generally comprise from 0% to about 5% by weight, preferably from about 0.1% to about 2%, of the compositions herein.
  • Antimicrobial, antiplaque agents can also optionally be present in the oral compositions of the subject invention, on the condition that they are compatible with the Actives.
  • Such agents may include, but are not limited to, triclosan, 2,4,4 , -trichloro-2'-hydroxydiphenyl ether, as described The Merck Index. 11th Ed. (1989), p. 1520 (entry No. 9573); chlorhexidine, ..Merck Index. No. 2090); alexidine (Merck Index. No. 222); hexetidine (Merck Index. No. 4624); sanguinarine (Merck Index. No. 8320); benzalkonium chloride (Merck Index. No. 1066); salicylanilide (Merck Index. No.
  • the antimicrobial antiplaque agents may comprise from 0% to about 6%, preferably from about 0.1% to about 5% by weight of the compositions of the subject invention.
  • Bleaching agents can also be present in the oral compositions of the subject invention.
  • Suitable bleaching agents include organic and inorganic oxidizing agents such as hydrogen peroxide, alkali metal peroxides and superoxide and organic peroxides such as monoper-oxyphthalates and perbenzoic derivatives. If present, such bleaching agents may comprise from 0% to about 6%, preferably from about 1 % to about 5% by weight of the compositions of the subject invention.
  • Nutrients can also be present in the oral composition of the subject invention, on condition that they are compatible with the Actives. Such agents may include folate, retinoids (Vitamin A), Vitamin C, Vitamin E. If present, the nutrients generally comprise from about 0.001% to about 10% by weight of the compositions of the subject invention.
  • a fluoride ion source typically is in the form of a water-soluble fluoride compound.
  • This water-soluble fluoride compound is typically present in the compositions of the subject invention in an amount sufficient to give a fluoride concentration of from about 0.0025% to about 5.0% by weight, preferably from about 0.005% to about 2.0% by weight.
  • Preferred fluoride sources are sodium fluoride, acidulated phosphate fluoride, and sodium monofluorophosphate.
  • compositions of the subject invention are in the form of dentifrices, especially toothpastes.
  • Components of toothpastes generally include a dental abrasive (from about 10% to about 50%), a surfactant (from about 0.5% to about 10%), a thickening agent (from about 0.1% to about 5%), a humectant (from about 10% to about 55%), a flavoring agent (from about 0.04% to about 2%), a sweetening agent (from about 0.1% to about 3%), a coloring agent (from about 0.01 % to about 0.5%) and water (from about 2% to about 45%).
  • compositions of the subject invention are mouth rinses, mouthwashes and mouth sprays.
  • Components of such mouthwashes and mouth sprays include water (from about 45% to about 95%), ethanol (from 0% to about 25%), humectant (from 0% to about 50%), surfactant (from about 0.01% to about 7%), flavoring agent (from about 0.04% to about 2%), sweetening agent (from about 0.1% to about 3%), and coloring agent (from about 0.001% to about 0.5%).
  • Such mouth rinses, mouthwashes and mouth sprays may also include an antiplaque agent (from about 0.1% to about 5%).
  • Other preferred compositions of the present invention are dental solutions.
  • Components of such dental solutions generally include water (from about 90% to about 99%), preservative (from about 0.01% to about 0.5%), thickening agent (from 0% to about 5%), flavoring agent (from about 0.04% to about 2%), sweetening agent (from about 0.1 % to about 3%), and surfactant (from 0% to about 5%). 5 Methods of Use
  • Another aspect of the subject invention involves methods of treating or preventing mouth odor, dental plaque, calculus and gingivitis, by application of compositions comprising a safe and effective amount of Actives, to tissues of the oral cavity.
  • compositions of the subject invention typically by administering an oral composition of the subject invention, as described hereinabove, to the oral cavity.
  • an amount of composition comprising at least about 0.001 g
  • the oral composition is a toothpaste, typically from about 0.3 grams to about 15 grams, preferably from about 0.5 grams to about 5 grams, more preferably from about 1 to about 2 grams, of
  • toothpaste is applied to an applicating device e.g., a toothbrush.
  • the applicating device is then contacted with the oral cavity surfaces in a manner such that the oral composition is contacted with tissue of the oral cavity, especially the teeth and gums.
  • the applicating device may be further used to effect an even distribution of the oral composition to
  • the application preferably lasts for a period of from about 15 seconds to about 10 minutes, more preferably from about 30 seconds to about 3 minutes, more preferably still from about 1 minute to about 2 minutes.
  • the toothpaste residue is typically removed from the tooth surface by using j 30 a liquid acceptable to the oral cavity, typically water, to rinse and be expectorated from the oral cavity.
  • the oral composition is a mouthwash, typically from about 1 ml. to about 20 ml., preferably from about 2 ml. to about 15 ml., most preferably from about 10 ml. to about 15 ml., of liquid mouthwash
  • the oral cavity 35 containing the antiplaque Active is introduced to the oral cavity.
  • the liquid mouthwash is then agitated for from about 10 seconds to about 10 min., preferably from about 15 seconds to about 3 min., more preferably from about 30 seconds to about 2 minutes, within the oral cavity to obtain an improved distribution of the mouthwash over the tissue of the oral cavity.
  • the mouthwash is typically expectorated from the oral cavity.
  • Application frequency is preferably from about 3 times weekly to about 4 times daily, more preferably from about once daily to about 3 times daily, more preferably still from about once to about twice daily.
  • the period of such treatment typically ranges from about one day to a lifetime.
  • compositions of the subject invention can be made using methods which are commonly used to produce oral care products.
  • dentifrice compositions of the subject invention are made using conventional processes.
  • the numbers listed are weight percentages of the compositions.
  • EXAMPLES XII-XVI The following are examples of mouthwash and dental rinse compositions of the subject invention and are made using conventinal processes. The amounts listed are weight percentages of the compositions. During manufacture, the pH of the following compositions is maintained at a minimum of pH 7.5.

Abstract

This invention involves a composition for treating or preventing dental plaque, calculus and gingivitis, or malodor of the oral cavity, comprising: (a) (i) a source of a safe and effective amount of zinc ions; (ii) a source of citrate ions; and (iii) one or more anticalculus agents selected from the group consisting of pyrophosphate, phosphonate, diphosphonate and pharmaceutically-acceptable linear condensed polyphosphates of the general formula: (PnO(3n+1)(n+2)- wherein n is an integer from 2 to 21; wherein the molar ratio of zinc:citrate is at most about 1:1; the molar ratio of zinc:pyro is at most about 1:1; and (b) and a pharmaceutically-acceptable topical oral carrier. This invention also involves methods for treating or preventing dental plaque, calculus and gingivitis, or malador of the oral cavity, comprising administering to the oral cavity of a human or other animal such a composition.

Description

ORAL COMPOSITIONS CONTAINING ANTIPLAQUE, ANTICALCULUS AGENTS
The subject invention relates to oral compositions, such as dentifrices and oral solutions, for the treatment or prevention of dental plaque, calculus and gingivitis, and mouth malodor. Background of the Invention
The mouth is a habitat for microbial growth and colonization. Within the mouth, the gums, lips, oral mucosa (cheek), palate, tongue and teeth provide surfaces for the colonization and accumulation of bacteria. Teeth are unique in the oral cavity because they have hard, non-shedding surfaces where bacteria and their products (dental plaque) can significantly accumulate, especially in approximal areas and along the gingival crevice.
Dental plaque is a rough sticky film on the teeth that is made up of saliva, bacteria and food particles which adheres tenaciously to teeth at points of irregularity or discontinuity. Within a few hours of teeth cleaning, a film of salivary mucins, consisting primarily of proteins, forms on the teeth. Various oral bacteria colonize the mucins and multiply, forming a layer of plaque. Carbohydrate food debris adheres to the mucins and is digested by some types of plaque- causing bacteria. The digestion both produces by-products which add to the plaque, and produces acid which erodes tooth enamel. The bacterial by-products produced in the oral cavity also include foul smelling gases which can result in malodor of the oral cavity.
The oral bacteria in dental plaque includes many gram positive and gram negative microorganisms embedded in an extracellular matrix of insoluble polysaccharides, firmly attached to teeth and other oral surfaces. The colonization of bacteria to form dental plaque follows an ecological pattern where a few pioneer aerobic species, mostly gram-positive streptococci, colonize enamel surfaces. The plaque then progresses through stages of increasing microbial complexity. Mature plaques, often found in protected regions of the teeth, such as cracks, approximal regions and in the gingival crevice, typically contain anaerobes. Saliva and crevicular fluid are a source of nutrients for the dental plaque. Local conditions affect the metabolic activity and composition of dental plaque. If not prevented or removed, plaque may become embedded with mineral salts, containing calcium and phosphate, to form a hard crusty deposit, calculus or tartar, on the teeth. Calculus may be white or yellowish in color or may be stained or discolored by extraneous agents. Calculus tends to be more unsightly than plaque and much more difficult to remove from the teeth. The toxins in plaque and calculus can irritate the gingival tissues surrounding the coated teeth, causing inflammation and destruction of the gums which can lead to other complications.
Zinc is an anticalculus agent; however, compositions containing zinc generally taste astringent and unpleasantly bitter. Like the chemical and biological activities, the negative aesthetics of the zinc cation are dose dependent: higher concentrations of zinc exhibit poorer aesthetics; therefore, increasing the concentration of free zinc tends to increase efficacy at the expense of aesthetics. This coupled behavior between efficacy and aesthetics has limited the utility of zinc in oral compositions. Pyrophosphate is also an anticalculus agent and, likewise, has an unpleasant taste which worsens with increased pyrophosphate concentration. By carefully formulating zinc and pyrophosphate-containing compositions, applicants have surprisingly found that the level of zinc in an oral composition can be increased, thus increasing the corresponding anticalculus effect, without greatly increasing the negative aesthetics of the composition.
It has been surprisingly found that it is possible to uncouple the efficacy and aesthetics of zinc containing compositions. When zinc is formulated with citrate and pyro at certain ratios of zincxitrate and zinc: pyro, it is possible to avoid the aesthetic negatives typically associated with the zinc ion.
It is an object of the subject invention to provide compositions for impeding calculus formation in the oral cavity. It is also an object of the subject invention to provide compositions for impeding dental plaque formation in the oral cavity. It is a further object of the subject invention to provide methods for impeding calculus formation in the oral cavity.
It is also an object of the subject invention to provide methods for impeding dental plaque formation in the oral cavity. Summary of the Invention
This invention involves a composition for treating or preventing dental plaque, calculus and gingivitis, or malodor of the oral cavity, comprising:
(a) (i) a source of a safe and effective amount of zinc ions; (ii) a source of citrate ions; and (iii) one or more anticalculus agents selected from the group consisting of pyrophosphate, phosphonate, diphosphonate and pharmaceutically-acceptable linear condensed poly¬ phosphates of the general formula: (PnO(3n+1 \)(n+2)" wherein n is an integer from 2 to 21 ; wherein the molar ratio of zincxitrate is at most about 1:1; the molar ratio of zinc:pyro is at most about 1:1; and
(b) and a pharmaceutically-acceptable topical oral carrier. This invention also involves methods for treating or preventing dental plaque, calculus and gingivitis, or malodor of the oral cavity, comprising administering to the oral cavity of a human or other animal such a composition.
Detailed Disclosure of the Invention The subject invention provides compositions effective against dental plaque formation, calculus formation, gingivitis, and mouth malodor.
"Pharmaceutically-acceptable topical oral carrier", as used herein, denotes a carrier for the active compounds of the subject invention (hereinafter "Actives") comprising solid or liquid filler diluents suitable for use in contact with the oral tissues of humans and lower animals without undue toxicity, incompatibility, instability, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio. Such topical oral carrier, when combined with Actives of the subject invention, results in a composition which is administered topically to the oral cavity. Preferably such compositions are held in the oral cavity for a period of time, and then largely expectorated rather than being swallowed. Such compositions include mouthwashes, mouth rinses, mouth sprays, dental treatment solutions, toothpastes, dental gels, tooth powders, prophylaxis pastes, lozenges, chewing gums and the like and are more fully described hereinafter. Dentifrices and mouthwashes are the preferred compositions.
"Pyro", as used herein, refers to pyrophosphate; phosphonate; diphosphonate; and pharmaceutically-acceptable polyphosphates including, but not limited to, linear condensed polyphosphates of the general formula: (PnO(3n+1 \)(n+2)"wherein n is an integer from 2 to
Figure imgf000006_0001
"Free pyro", as used herein, refers to pyro that is not bound or chelated to the transition metal, zinc.
"Free zinc", as used herein, refers to hydrated zinc cationic species, such as Zn(H2θ)62+. As used herein, percentages listed are weight percentage of composition unless otherwise specified.
The amounts of pyro and citrate are expressed in terms of a ratio to the amount of zinc in the oral composition. On a molar basis, the amount of citrate relative to zinc is at least one when the molar amount of zinc is one (i.e. the molar, ratio of zincxitrate is at most about 1:1); and the amount of pyro relative to zinc is at least one when the molar amount of zinc is one (i.e. the molar ratio of zinc:pyro is at most about 1:1). Preferably the zincxitrate ratio is from about 1:1 to about 1:20; more preferably from about 1:1 to about 1:4, more still preferably from about 1:1 to about 1:3. Preferred is a zinc: pyro ratio from about 1:1 to about 1:20 more preferably from about 1:1 to about 1:8, more preferably still from about 1:1.5 to about 1:6. Also preferred is a zincxitrate.pyro ratio wherein the sum of the molar ratio amounts of citrate ions and pyro ions is from about 2 to about 9, more preferably from about 3 to about 9, when the ratio amount of zinc is 1.
The amount of zinc suitable for the purposes of the subject invention is from about 0.005% to about 5% Zn; more preferably from about 0.03% to about 3% Zn; more preferably still from about 0.05% to about 2% Zn. In dentifrice compositions, the preferred amounts of zinc are from about 0.1% to about 2%, more preferably from about 0.25% to about 1%. In mouthwashes, mouth rinses, mouth sprays and dental solutions, the preferred amount of zinc is from about 0.005% to about 1%, more preferably from about 0.05% to about 0.5%.
The amount of citrate anion suitable for the purposes of the subject invention is from about 0.015% to about 25% citrate. In dentifrice compositions, the preferred amounts of citrate anion are from about 0.2 % to about 17%, more preferably from about 0.7% to about 12%, more preferably still from about 1.5% to about 5%. In mouthwashes, mouth rinses, mouth sprays and dental solutions, the preferred amount of citrate anion is from about 0.01% to about 12%, more preferably from about 0.1% to about 6%, more preferably still from about 0.15% to about 1 %.
The amount of pyro anion suitable for the purposes of the subject invention is from about 0.015% to about 25% pyro. In dentifrice compositions, the preferred amounts of pyro ion are from about 0.25% to about 16%, more preferably from about 0.6% to about 11%. In mouthwashes, mouth rinses, mouth sprays and dental solutions, the preferred amount of pyro anion is from about 0.01 % to about 11 %, more preferably from about 0.1% to about 5%.
Suitable sources of zinc ions include zinc oxides, zinc halides, zinc-strong acid complexes, Zn(N03)2, Zn(CIO_ )2, ZnSO_ , and zinc- organic acids sources such as zinc lactate, tartrate, citrate salts, zinc citrate trihydrate and sodium zinc citrate. Zinc sources that are unacceptable are zinc ethylenediaminetetraacetate (ZnEDTA) and zinc nitrilotriacetate (ZnNTA). Preferred sources of zinc ions include zinc oxide (ZnO) and zinc nitrate; more preferred is ZnO.
Suitable sources of citrate ions include zinc citrate; citric acid; alkali metal salts of citric acid, especially sodium citrate and potassium citrate; pharmaceutically acceptable hydrated and dehydrated salts of any of the above; and mixtures of any of the above. Suitable sources of pyro ions are disclosed in U.S. Pat. No.
4,885,155, issued December 5, 1989 to Parran & Sakkab; U.S. Pat. No. 3,678,154, issued July 18, 1972 to Widder et al.; U.S. Pat. No. 3,737,522, issued June 5, 1973 to Francis et al.; and U.S. Pat. No. 4,627,977, issued December 9, 1986 to Gaffer et al.; each is incorporated herein by reference. Suitable pyro ion sources include tetrasodium pyrophosphate, sodium acid pyrophosphate (Na2H2P2 >7), tetrapotassium pyrophosphate (K4P2O7); phosphates including, but not limited to, linear condensed polyphosphates of the general an
Figure imgf000008_0001
integer from 2 to 21; phosphonates and diphosphonates, such as EHDP (ethane-1-hydroxy-1,1-diphosphonate) and AHP (azacyclo- heptane-2,2-diphosphonic acid); pharmaceutically-acceptable alkali metal salts of pyrophosphates, polyphosphates, phosphonates and diphosphonates; and mixtures of any of the above. Preferred pyro ions are pyrophosphate ions; preferred polyphosphate ions are those of the above formula wherein n is 6, 13, and 21. Preferred alkali metals are sodium and potassium for solubility reasons; mixtures of alkali metal salts are acceptable.
The pH of oral compositions of the subject invention is critical but can be varied to some extent. Preferably the oral compositions are at a pH of from about 6 to about 9, more preferably from about 6.25 to about 8.75, more preferably still from about 7.5 to about 8.5.
During manufacture of a composition of this invention, the conditions for addition of each component should be optimized such that the pH of the mixture does not drop below formulation pH at any time during mixing the indredients.
Compositions By "safe and effective amount" as used herein is meant an amount of compound or composition sufficient to induce a significant positive modification in the condition to be treated, but low enough to avoid serious side effects (at a reasonable benefit/risk ratio), within the scope of sound medical judgment. The safe and effective amount of the compound or composition will vary with the particular condition being treated, the age and physical condition of the patient being treated, the severity of the condition, the duration of the treatment, the nature of concurrent therapy, the specific compound or composition employed, the particular pharmaceutically-acceptable carrier utilized, and like factors.
By the term "comprising", as used herein, is meant that various additional components can be conjointly employed in the compositions of this invention. Components of the topical, oral carrier are suitable for administration to the oral cavity of a human or lower animal and are compatible with one another and the other components, especially with the Actives, used in an oral composition of the subject invention. The term "compatible" as used herein, means that the components are capable of being co-mingled with one another, in a manner such that there is no interaction which would substantially reduce the efficacy of the oral composition under ordinary use conditions.
Preferred topical, oral carriers provide the desired characteristics for mouthwashes, mouth rinses, mouth sprays, dental treatment solutions, toothpastes, dental gels, toothpowders, prophylaxis pastes, lozenges, chewing gums, and the like. The topical, oral carriers of the subject invention comprise components typically used in such compositions which are well known to a skilled practitioner. Such components include, but are not limited to, anticaries agents, antiplaque agents, anticalculus agents, dental abrasives, surfactants, flavoring agents, sweetening agents, binders, humectants, thickening agents, buffering agents, preservatives, coloring agents and pigments, ethanol and water. Water is an optional component of the topical, oral carriers of the compositions of the subject invention. Water employed in the preparation of the commercially suitable compositions should preferably be of low ion content and free of organic impurities. Water preferably comprises from about 2% to about 99%, more preferably from about 20% to about 95% of the compositions of the subject invention. When in the form of toothpaste, the compositions preferably comprise from about 2% to about 80%, more preferably from about 30% to about 60%, water, while mouthwashes comprise preferably from about 45% to about 99%, more preferably from about 75% to about 98%, water.
Dental abrasives useful in the topical, oral carriers of the compositions of the subject invention include many different materials. The material selected must be one which is compatible with the composition of interest and does not excessively abrade dentin. These include, for example, silicas, including gels and precipitates, calcium carbonate, dicalcium orthophosphate dihydrate, calcium pyrophosphate, tricalcium phosphate, calcium polymeta-phosphate, insoluble sodium polymeta-phosphate, hydrated alumina, • and resinous abrasive materials such as particulate condensation products of urea and formaldehyde, and other materials such as those disclosed by Cooley et al. in U.S. Pat. No. 3,070,510, issued December 25, 1962, incorporated herein by reference. Mixtures of abrasives may also be used.
Silica dental abrasives, of various types, can provide the unique benefits of exceptional dental cleaning and polishing performance without unduly abrading tooth enamel or dentin. For this reason they are preferred for use herein.
The silica abrasive polishing materials useful herein, as well as the other abrasives, generally have an average particle size ranging between about 0.1 and 30 microns, preferably between about 5 and 15 microns. The silica abrasive can be precipitated silica or silica gels such as the silica xerogels described in U.S. Pat. No. 3,538,230, issued March 2, 1970 to Pader et al., and in U.S. Pat. No. 3,862,307, issued June 21, 1975 to DiGiulio, both incorporated herein by reference. Preferred are the silica xerogels marketed under the tradename Syloid® by the W.R. Grace & Company, Davidson Chemical Division. Preferred precipitated silica materials include those marketed by the J. M. Huber Corporation under the tradename, Zeodent®, particularly the silica carrying the designation Zeodent 119®. These silica abrasives are described in U.S. Pat. No. 4,340,583, Wason, issued July 20, 1982, incorporated herein by reference.
Mixtures of abrasives may be used. The amount of abrasive in the compositions described herein ranges from about 6% to about 70%, preferably from about 15% to about 50%, when the dentifrice is a toothpaste. Higher levels, as high as 90%, may be used if the composition is a tooth powder.
Flavoring agents can also be added to the oral compositions of the subject invention to make them more palatable. Suitable flavoring agents include menthol, oil of wintergreen, oil of peppermint, oil of spearmint, oil of sassafras, and oil of clove. Flavoring agents are generally included in the subject compositions in amounts of from 0% to about 3%, preferably from about 0.04% to about 2% by weight.
Coloring agents may be added to compositions of the subject invention to improve appearance. If present, coloring agents typically are included at levels of from about 0.001 % to about 0.5% by weight. Sweetening agents are also preferred in the compositions of the subject invention to make them more palatable. Sweetening agents which can be used include aspartame, acesulfame, saccharin salts, dextrose, glucose, levulose thaumatin, D-tryptophan, dihydrochalcones, and cyclamate salts. Saccharin salts are preferred. Sweetening agents are generally used in the subject compositions in amounts of from 0% to about 6%, preferably from about 0.005% to about 5% by weight.
Oral compositions can also contain a surfactant. Suitable surfactants are those which are reasonably stable and form suds throughout a wide pH range, including nonsoap anionic, nonionic, cationic, zwitterionic and amphoteric organic synthetic detergents, and compatible mixtures thereof. Many of these suitable surfactants are disclosed in U.S. Pat. No. 4,051,234, issued to Gieske et al. on September 27, 1977, and in U.S. Pat. No. 3,959,458 issued to Agricola, Briner, Granger and Widder on May 25, 1976, both of which are incorporated herein by reference. Surfactants are typically present in compositions of the subject invention at a level of from 0% to about 20%, preferably from about 0.1, more preferably from about 1% to about 4% by weight. Surfactants may also be used as solubilizing agents to help retain sparingly soluble components, e.g., some flavoring agents, in solutions. Surfactants suitable for this purpose include polysorbates and poloxamers. Preferred are surfactants which are non-ionic at the formulation pH of the compositions.
In preparing oral compositions of the subject invention, it is desirable to add binders and/or thickening agents, particularly to toothpaste compositions to provide a desired consistency. Suitable binders for these compositions are natural gums such as gum karaya, gum arabic, and gum tragacanth; polysaccharide gums such as xanthan gum; and other natural products such as carrageenan; chemically modified natural products such as those based on cellulose esters, that is, carboxyimethylcellulose (CMC), hydroxyethylcellulose (HEC), and hydroxypropylcellulose (HPC); and synthetic binders such as polyvinylpyrrolidone; and water soluble salts of cellulose ethers such as sodium carboxymethyl cellulose and sodium carboxymethyl hydroxyethyl cellulose. Carboxyvinyl polymer binders are less desirable, but may be used. Colloidal magnesium aluminum silicate or finely divided silica can be used as part of the thickening agent to further improve texture. Blends and mixtures of the suitable binders may significantly improve the characteristics of compositions made therewith. Preferred binders are chemically modified celluloses such as CMC or HEC; more preferred is HEC. Binders and thickening agents are generally present in the compositions of the subject invention in amounts of from about 0.1% to 10%, preferably from about 0.25% to about 7.5%, more preferably from about 0.5% to about 3.5%.
Another optional component of the oral carriers of the compositions of the subject invention is a humectant. The humectant serves to keep toothpaste compositions from hardening upon exposure to air, and to give mouthwash and toothpaste compositions a moist feel to the mouth. Certain humectants can also impart desirable sweetness of flavor to mouthwash and toothpaste compositions. The humectant, on a pure humectant basis, generally comprises from 0% to about 70%, preferably from about 2% to about 55%, by weight of the compositions herein. Suitable humectants for use in compositions of the subject invention include edible polyhydric alcohols such as glycerin, sorbitol, xylitol, polyethylene glycol, and propylene glycol, especially sorbitol and glycerin.
Opacifiers may also be used in toothpastes of the subject invention to render the toothpaste opaque. Suitable opacifiers include titanium dioxide and some abrasives including, for example, magnesium aluminum silicate. Opacifiers generally comprise from 0% to about 4%, preferably from about 0.5% to about 3% by weight of the compositions herein.
Other optional components of the compositions of the subject invention are preservatives. The preservatives prevent microbial growth in the compositions. Suitable preservatives include methylparaben, propylparaben, benzoates and ethanol. If the preservative is ethanol, it generally comprises from 0% to about 35% by weight, preferably from about 5% to about 15%, of the compositions herein. Other preservatives generally comprise from 0% to about 5% by weight, preferably from about 0.1% to about 2%, of the compositions herein.
Antimicrobial, antiplaque agents can also optionally be present in the oral compositions of the subject invention, on the condition that they are compatible with the Actives. Such agents may include, but are not limited to, triclosan, 2,4,4,-trichloro-2'-hydroxydiphenyl ether, as described The Merck Index. 11th Ed. (1989), p. 1520 (entry No. 9573); chlorhexidine, ..Merck Index. No. 2090); alexidine (Merck Index. No. 222); hexetidine (Merck Index. No. 4624); sanguinarine (Merck Index. No. 8320); benzalkonium chloride (Merck Index. No. 1066); salicylanilide (Merck Index. No. 8299); domiphen bromide (Merck Index. No. 3411); cetylpyridinium chloride, (CPC) (Merck Index. No. 2024); tetradecylpyridinium chloride, (TPC); N-tetradecyl- 4-ethylpyridinium chloride (TDEPC); octenidine; delmopinol, octapinol, and other piperidino derivatives; nicin preparations; antibiotics such as augmentin, amoxicillin, tetracycline, doxycycline, minocycline, and metronidazole; and peroxides, such as cylium peroxide, hydrogen peroxide, and magnesium monoperthalate and its analogs as described in U.S. Patent No. 4,670,252; and analogs and salts of the above antimicrobial antiplaque agents. If present, the antimicrobial antiplaque agents may comprise from 0% to about 6%, preferably from about 0.1% to about 5% by weight of the compositions of the subject invention.
Bleaching agents can also be present in the oral compositions of the subject invention. Suitable bleaching agents include organic and inorganic oxidizing agents such as hydrogen peroxide, alkali metal peroxides and superoxide and organic peroxides such as monoper-oxyphthalates and perbenzoic derivatives. If present, such bleaching agents may comprise from 0% to about 6%, preferably from about 1 % to about 5% by weight of the compositions of the subject invention. Nutrients can also be present in the oral composition of the subject invention, on condition that they are compatible with the Actives. Such agents may include folate, retinoids (Vitamin A), Vitamin C, Vitamin E. If present, the nutrients generally comprise from about 0.001% to about 10% by weight of the compositions of the subject invention.
Other optional ingredients include a safe and effective amount of a fluoride ion source, which typically is in the form of a water-soluble fluoride compound. This water-soluble fluoride compound is typically present in the compositions of the subject invention in an amount sufficient to give a fluoride concentration of from about 0.0025% to about 5.0% by weight, preferably from about 0.005% to about 2.0% by weight. Preferred fluoride sources are sodium fluoride, acidulated phosphate fluoride, and sodium monofluorophosphate. U.S. Pat. No. 3,678,154, issued July 18, 1972 to Widder et al.', discloses such salts as well as others, and is incorporated herein by reference.
Preferred compositions of the subject invention are in the form of dentifrices, especially toothpastes. Components of toothpastes generally include a dental abrasive (from about 10% to about 50%), a surfactant (from about 0.5% to about 10%), a thickening agent (from about 0.1% to about 5%), a humectant (from about 10% to about 55%), a flavoring agent (from about 0.04% to about 2%), a sweetening agent (from about 0.1% to about 3%), a coloring agent (from about 0.01 % to about 0.5%) and water (from about 2% to about 45%).
Other preferred compositions of the subject invention are mouth rinses, mouthwashes and mouth sprays. Components of such mouthwashes and mouth sprays include water (from about 45% to about 95%), ethanol (from 0% to about 25%), humectant (from 0% to about 50%), surfactant (from about 0.01% to about 7%), flavoring agent (from about 0.04% to about 2%), sweetening agent (from about 0.1% to about 3%), and coloring agent (from about 0.001% to about 0.5%). Such mouth rinses, mouthwashes and mouth sprays may also include an antiplaque agent (from about 0.1% to about 5%). Other preferred compositions of the present invention are dental solutions. Components of such dental solutions generally include water (from about 90% to about 99%), preservative (from about 0.01% to about 0.5%), thickening agent (from 0% to about 5%), flavoring agent (from about 0.04% to about 2%), sweetening agent (from about 0.1 % to about 3%), and surfactant (from 0% to about 5%). 5 Methods of Use
Another aspect of the subject invention involves methods of treating or preventing mouth odor, dental plaque, calculus and gingivitis, by application of compositions comprising a safe and effective amount of Actives, to tissues of the oral cavity. Such
10 compositions are described hereinabove.
These methods involve administering a safe and effective amount of Actives, typically by administering an oral composition of the subject invention, as described hereinabove, to the oral cavity. Generally an amount of composition comprising at least about 0.001 g
15 of the Actives is effective. The teeth and other oral cavity tissues are exposed to the Actives.
When the oral composition is a toothpaste, typically from about 0.3 grams to about 15 grams, preferably from about 0.5 grams to about 5 grams, more preferably from about 1 to about 2 grams, of
20 toothpaste is applied to an applicating device e.g., a toothbrush. The applicating device is then contacted with the oral cavity surfaces in a manner such that the oral composition is contacted with tissue of the oral cavity, especially the teeth and gums. The applicating device may be further used to effect an even distribution of the oral composition to
25 the tooth surface, for example by brushing. The application preferably lasts for a period of from about 15 seconds to about 10 minutes, more preferably from about 30 seconds to about 3 minutes, more preferably still from about 1 minute to about 2 minutes. Following application, the toothpaste residue is typically removed from the tooth surface by using j 30 a liquid acceptable to the oral cavity, typically water, to rinse and be expectorated from the oral cavity.
When the oral composition is a mouthwash, typically from about 1 ml. to about 20 ml., preferably from about 2 ml. to about 15 ml., most preferably from about 10 ml. to about 15 ml., of liquid mouthwash
35 containing the antiplaque Active is introduced to the oral cavity. The liquid mouthwash is then agitated for from about 10 seconds to about 10 min., preferably from about 15 seconds to about 3 min., more preferably from about 30 seconds to about 2 minutes, within the oral cavity to obtain an improved distribution of the mouthwash over the tissue of the oral cavity. Following agitation, the mouthwash is typically expectorated from the oral cavity.
Application frequency is preferably from about 3 times weekly to about 4 times daily, more preferably from about once daily to about 3 times daily, more preferably still from about once to about twice daily.
The period of such treatment typically ranges from about one day to a lifetime.
Oral Composition Examples The following non-limiting examples further describe and demonstrate preferred embodiments within the scope of the subject invention. The examples are given solely for illustration and are not to be construed as limitations of the subject invention as many variations are possible without departing from the spirit and scope of the subject invention.
The compositions of the subject invention can be made using methods which are commonly used to produce oral care products. EXAMPLES l-Xl
The following are examples of dentifrice compositions of the subject invention and are made using conventional processes. The numbers listed are weight percentages of the compositions. During
Figure imgf000016_0001
Figure imgf000017_0001
Slurry pH: 7.1 to 7.3
Figure imgf000017_0002
Figure imgf000018_0001
Slurry pH: 7.5 to 8.5
EXAMPLES XII-XVI The following are examples of mouthwash and dental rinse compositions of the subject invention and are made using conventinal processes. The amounts listed are weight percentages of the compositions. During manufacture, the pH of the following compositions is maintained at a minimum of pH 7.5.
Figure imgf000018_0002
Figure imgf000019_0001
While particular embodiments of the subject invention have been described, it will be obvious to those skilled in the art that various changes and modifications to the subject invention can be made without departing from the spirit and scope of the invention. It is intended to cover, in the appended claims, all such modifications that are within the scope of the subject invention.

Claims

Claims
1. A composition for treating or preventing dental plaque, calculus and gingivitis, or malodor of the oral cavity, comprising: (a) (i) a source of a safe and effective amount of zinc ions;
(ii) a source of citrate ions; and (iii) one or more anticalculus agents selected from pyrophosphate, phosphonate, diphosphonate and pharmaceutically- acceptable linear condensed poly-phosphates of the general formula: (PnO(3n+i ))(n+^_ wherein n is an integer from 2 to 21 ; wherein the molar ratio of zincxitrate is at most 1 :1 ; the molar ratio of zinc: pyro is at most 1 :1 ; and (b) a pharmaceutically-acceptable topical oral carrier.
2. The composition according to Claim 1 wherein the molar ratio of zinc ionsxitrate ions is from 1 :1 to 1 :20, preferably from 1 :1 to 1 :5, more preferably from 1 :1 to 1 :4, and the molar ratio of zinc ions to the anticalculus agents is from 1 :1 to 1 :20, preferably from 1 :1 to 1 :8, more preferably from 1:1 to 1 :5.
3. The composition according to any of Claims 1-2 wherein the composition is at a pH of from 6 to 9, preferably from 7.5 to 8.5 and the sum of the molar ratio amounts of citrate ions and anticalculus agents is from 3 to 9.
4. The composition of any of Claims 1-3 which is in the form of a dentifrice, preferably wherein the pharmaceutically-acceptable topical oral carrier comprises a dental abrasive.
5. The composition according to any of Claims 1-4 which comprises from 0.1 % to 2%, preferably from 0.25% to 1 %, by weight zinc ions.
6. A composition according to any of Claims 1-3 which is in the form of a mouth rinse, preferably wherein the pharmaceutically-acceptable topical oral carrier comprises a material selected from a humectant, ethanol, and a nonionic surfactant.
7. The composition according to any of Claims 1-3 and 6 comprising from 0.005% to 0.5% by weight zinc ions.
8. The composition according to any of Claims 1-7 wherein the anticalculus agent is selected from pyrophosphate, EHDP, AHP, and linear condensed polyphosphates of the general formula: n is 6, 13, or 21 , preferably the anticalc
Figure imgf000021_0001
agent s pyrop osp ate.
9. The composition according to any of Claims 1-8 which comprises a source of fluoride ions yielding from 0.0025% to 5% by weight fluoride ions.
10. A method for treating or preventing dental plaque, calculus or malador of the oral cavity comprising administering to the oral cavity of a human or lower mammal a safe and effective amount of a composition selected from Claims 1-9.
PCT/US1993/011787 1992-12-18 1993-12-06 Oral compositions containing antiplaque, anticalculus agents WO1994014407A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP6515185A JPH08505843A (en) 1992-12-18 1993-12-06 Oral composition containing antiplaque and anticalculus agent
BR9307688-6A BR9307688A (en) 1992-12-18 1993-12-06 Oral compositions containing anti-plaque, anti-calculus agents
AU57400/94A AU5740094A (en) 1992-12-18 1993-12-06 Oral compositions containing antiplaque, anticalculus agents
EP94903459A EP0675706A1 (en) 1992-12-18 1993-12-06 Oral compositions containing antiplaque, anticalculus agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99333692A 1992-12-18 1992-12-18
US07/993,336 1992-12-18
US14877693A 1993-11-16 1993-11-16
US08/148,776 1993-11-16

Publications (1)

Publication Number Publication Date
WO1994014407A1 true WO1994014407A1 (en) 1994-07-07

Family

ID=26846152

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/011787 WO1994014407A1 (en) 1992-12-18 1993-12-06 Oral compositions containing antiplaque, anticalculus agents

Country Status (10)

Country Link
EP (1) EP0675706A1 (en)
JP (1) JPH08505843A (en)
CN (1) CN1095263A (en)
AU (1) AU5740094A (en)
BR (1) BR9307688A (en)
CA (1) CA2151913A1 (en)
CZ (1) CZ156795A3 (en)
HU (1) HUT72041A (en)
MX (1) MX9400053A (en)
WO (1) WO1994014407A1 (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455023A (en) * 1993-06-10 1995-10-03 Church & Dwight Co., Inc. Liquid mouthwash containing a particulate bicarbonate suspension
EP0735855A1 (en) * 1993-12-22 1996-10-09 Smithkline Beecham Corporation Tooth whitening preparations
EP0712624A3 (en) * 1994-11-14 1998-08-26 Colgate-Palmolive Company Dentifrice compositions having improved anticalculus properties
US5833955A (en) * 1996-11-14 1998-11-10 The Research Foundation Of State University Of New York Diagnostic tests to assess a persons oral malodor capacity and potential for developing periodontitis
US5939052A (en) * 1996-11-21 1999-08-17 The Procter & Gamble Company Dentifrice compositions containing polyphosphate and fluoride
US6190644B1 (en) * 1996-11-21 2001-02-20 The Procter & Gamble Company Dentifrice compositions containing polyphosphate and monofluorophosphate
WO2002092038A2 (en) * 2001-05-15 2002-11-21 The Procter & Gamble Company Oral care compositions
US6521216B1 (en) 1999-11-12 2003-02-18 The Procter & Gamble Company Dual phase stannous oral compositions
US6555094B1 (en) 1999-11-12 2003-04-29 The Procter & Gamble Company Stannous oral compositions
US6607711B2 (en) 1997-10-07 2003-08-19 Ejvind Jersie Pedersen Mouth hygienic composition for the treatment of halitosis
US6706277B2 (en) * 2001-05-15 2004-03-16 The Procter & Gamble Company Confectionery compositions
US6713049B1 (en) 1999-11-12 2004-03-30 The Procter & Gamble Company Oral compositions providing optimal surface conditioning
US6726897B2 (en) * 2001-05-15 2004-04-27 The Procter & Gamble Co. Confectionery compositions
EP1508323A1 (en) * 2003-08-20 2005-02-23 Unilever N.V. Use of oral care composition containing zinc salt
WO2007076444A3 (en) * 2005-12-21 2007-08-16 Colgate Palmolive Co Improved oral compositions comprising zinc citrate and/or tocopherol agents
EP2057978A1 (en) 2007-11-09 2009-05-13 The Procter and Gamble Company Oral stannous compositions
US8778311B2 (en) 2006-03-22 2014-07-15 The Procter & Gamble Company Oral zinc compositions
US9968803B2 (en) 2009-10-29 2018-05-15 Colgate-Palmolive Company Low water stannous fluoride plus zinc citrate dentifrice with improved stability, rheology, and efficacy
US10258550B2 (en) 1999-11-12 2019-04-16 The Procter & Gamble Company Method of protecting teeth against erosion
US10470985B2 (en) 1999-11-12 2019-11-12 The Procter & Gamble Company Method of protecting teeth against erosion
US10596086B2 (en) 2012-06-21 2020-03-24 The Procter & Gamble Company Reduction of tooth staining derived from cationic antibacterials
US11191709B2 (en) 2019-04-26 2021-12-07 The Procter & Gamble Company Reduction of tooth staining derived from cationic antimicrobials

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350438B1 (en) * 1998-02-27 2002-02-26 The Procter & Gamble Company Oral care compositions comprising chlorite and methods
US6846478B1 (en) * 1998-02-27 2005-01-25 The Procter & Gamble Company Promoting whole body health
JPH11246376A (en) * 1998-02-27 1999-09-14 Sunstar Inc Composition for oral cavity
JP2001151651A (en) * 1999-11-26 2001-06-05 Earth Chem Corp Ltd Composition for oral cavity
ATE401089T1 (en) * 2000-06-30 2008-08-15 Procter & Gamble ORAL PREPARATIONS CONTAINING ANTIMICROBIAL ACTIVE INGREDIENTS FOR THE PREVENTION OF SYSTEMIC DISEASES
JP3957293B2 (en) * 2003-01-27 2007-08-15 花王株式会社 Oral composition
DE10311171A1 (en) * 2003-03-12 2004-09-23 Henkel Kgaa Oral and dental care composition with antitartar, antiplaque and anti-discoloration action, containing cationic antibacterial agent, aza-cycloalkane-diphosphonic acid and xanthan gum or carboxymethyl cellulose
JP2018002660A (en) * 2016-07-01 2018-01-11 Nsファーファ・ジャパン株式会社 Oral composition
JP2022099625A (en) * 2020-12-23 2022-07-05 小林製薬株式会社 Composition for oral cavity

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0251542A2 (en) * 1986-06-27 1988-01-07 Lion Corporation Oral composition
EP0295116A1 (en) * 1987-06-12 1988-12-14 Unilever Plc Oral compositions
EP0309414A2 (en) * 1987-08-28 1989-03-29 AVANTGARDE S.p.A. Chewing gum having antitartar activity
EP0331415A1 (en) * 1988-03-01 1989-09-06 Unilever Plc Anticalculus oral compostions
US4869898A (en) * 1988-01-25 1989-09-26 Colgate-Palmolive Co. Anticalculus oral composition
EP0426213A1 (en) * 1989-10-05 1991-05-08 Unilever N.V. Oral compositions
WO1992010994A1 (en) * 1990-12-18 1992-07-09 The Procter & Gamble Company Oral compositions effective against plaque and gingivitis
GB2260700A (en) * 1991-10-17 1993-04-28 Colgate Palmolive Co Desensitising antitartar dentifrices

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0251542A2 (en) * 1986-06-27 1988-01-07 Lion Corporation Oral composition
EP0295116A1 (en) * 1987-06-12 1988-12-14 Unilever Plc Oral compositions
EP0309414A2 (en) * 1987-08-28 1989-03-29 AVANTGARDE S.p.A. Chewing gum having antitartar activity
US4869898A (en) * 1988-01-25 1989-09-26 Colgate-Palmolive Co. Anticalculus oral composition
EP0331415A1 (en) * 1988-03-01 1989-09-06 Unilever Plc Anticalculus oral compostions
EP0426213A1 (en) * 1989-10-05 1991-05-08 Unilever N.V. Oral compositions
WO1992010994A1 (en) * 1990-12-18 1992-07-09 The Procter & Gamble Company Oral compositions effective against plaque and gingivitis
GB2260700A (en) * 1991-10-17 1993-04-28 Colgate Palmolive Co Desensitising antitartar dentifrices

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"oral compositions", RESEARCH DISCLOSURE, no. 321, January 1991 (1991-01-01), EMSWORTH GB, pages 80 - 81 *

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455023A (en) * 1993-06-10 1995-10-03 Church & Dwight Co., Inc. Liquid mouthwash containing a particulate bicarbonate suspension
EP0735855A1 (en) * 1993-12-22 1996-10-09 Smithkline Beecham Corporation Tooth whitening preparations
EP0735855A4 (en) * 1993-12-22 1996-12-04 Smithkline Beecham Corp Tooth whitening preparations
EP0712624A3 (en) * 1994-11-14 1998-08-26 Colgate-Palmolive Company Dentifrice compositions having improved anticalculus properties
US5833955A (en) * 1996-11-14 1998-11-10 The Research Foundation Of State University Of New York Diagnostic tests to assess a persons oral malodor capacity and potential for developing periodontitis
US5939052A (en) * 1996-11-21 1999-08-17 The Procter & Gamble Company Dentifrice compositions containing polyphosphate and fluoride
US6190644B1 (en) * 1996-11-21 2001-02-20 The Procter & Gamble Company Dentifrice compositions containing polyphosphate and monofluorophosphate
US6607711B2 (en) 1997-10-07 2003-08-19 Ejvind Jersie Pedersen Mouth hygienic composition for the treatment of halitosis
US10369090B2 (en) 1999-11-12 2019-08-06 The Procter & Gamble Company Method of protecting teeth against erosion
US10376451B2 (en) 1999-11-12 2019-08-13 The Procter & Gamble Company Method of protecting teeth against erosion
US10470985B2 (en) 1999-11-12 2019-11-12 The Procter & Gamble Company Method of protecting teeth against erosion
US6521216B1 (en) 1999-11-12 2003-02-18 The Procter & Gamble Company Dual phase stannous oral compositions
US6555094B1 (en) 1999-11-12 2003-04-29 The Procter & Gamble Company Stannous oral compositions
US10258550B2 (en) 1999-11-12 2019-04-16 The Procter & Gamble Company Method of protecting teeth against erosion
US6713049B1 (en) 1999-11-12 2004-03-30 The Procter & Gamble Company Oral compositions providing optimal surface conditioning
US10258549B2 (en) 1999-11-12 2019-04-16 The Procter & Gamble Company Method of protecting teeth against erosion
US10702460B2 (en) 1999-11-12 2020-07-07 The Procter & Gamble Company Method of protecting teeth against erosion
US6702999B2 (en) 2001-05-15 2004-03-09 The Procter & Gamble Co. Oral care compositions
WO2002092038A2 (en) * 2001-05-15 2002-11-21 The Procter & Gamble Company Oral care compositions
US6726897B2 (en) * 2001-05-15 2004-04-27 The Procter & Gamble Co. Confectionery compositions
US6706277B2 (en) * 2001-05-15 2004-03-16 The Procter & Gamble Company Confectionery compositions
WO2002092038A3 (en) * 2001-05-15 2003-05-08 Procter & Gamble Oral care compositions
EP1508323A1 (en) * 2003-08-20 2005-02-23 Unilever N.V. Use of oral care composition containing zinc salt
WO2007076444A3 (en) * 2005-12-21 2007-08-16 Colgate Palmolive Co Improved oral compositions comprising zinc citrate and/or tocopherol agents
AU2012203181B2 (en) * 2005-12-21 2012-09-13 Colgate-Palmolive Company Improved oral compositions comprising zinc citrate and/or tocopherol agents
AU2010202023B2 (en) * 2005-12-21 2012-03-01 Colgate-Palmolive Company Improved oral compositions comprising zinc citrate and/or tocopherol agents
AU2006330508B2 (en) * 2005-12-21 2010-02-25 Colgate-Palmolive Company Improved oral compositions comprising zinc citrate and/or tocopherol agents
US8778311B2 (en) 2006-03-22 2014-07-15 The Procter & Gamble Company Oral zinc compositions
US8906347B2 (en) 2007-11-09 2014-12-09 The Procter & Gamble Co. Oral stannous compositions
EP2057978A1 (en) 2007-11-09 2009-05-13 The Procter and Gamble Company Oral stannous compositions
US9968803B2 (en) 2009-10-29 2018-05-15 Colgate-Palmolive Company Low water stannous fluoride plus zinc citrate dentifrice with improved stability, rheology, and efficacy
US10668306B2 (en) 2009-10-29 2020-06-02 Colgate-Palmolive Company Low water stannous fluoride plus zinc citrate dentifrice with improved stability, rheology, and efficacy
US10682532B2 (en) 2009-10-29 2020-06-16 Colgate-Palmolive Company Low water stannous fluoride plus zinc citrate dentifrice with improved stability, rheology, and efficacy
US11147992B2 (en) 2009-10-29 2021-10-19 Colgate-Palmolive Company Low water stannous fluoride plus zinc citrate dentifrice with improved stability, rheology, and efficacy
US11285342B2 (en) 2009-10-29 2022-03-29 Colgate-Palmolive Company Low water stannous fluoride plus zinc citrate dentifrice with improved stability, rheology, and efficacy
US10596086B2 (en) 2012-06-21 2020-03-24 The Procter & Gamble Company Reduction of tooth staining derived from cationic antibacterials
US11253451B2 (en) 2012-06-21 2022-02-22 The Procter & Gamble Company Reduction of tooth staining derived from cationic antibacterials
US11191709B2 (en) 2019-04-26 2021-12-07 The Procter & Gamble Company Reduction of tooth staining derived from cationic antimicrobials
US11826452B2 (en) 2019-04-26 2023-11-28 The Procter & Gamble Company Reduction of tooth staining derived from cationic antimicrobials

Also Published As

Publication number Publication date
CZ156795A3 (en) 1996-01-17
BR9307688A (en) 1999-09-08
HU9501784D0 (en) 1995-08-28
MX9400053A (en) 1994-07-29
AU5740094A (en) 1994-07-19
CA2151913A1 (en) 1994-07-07
JPH08505843A (en) 1996-06-25
EP0675706A1 (en) 1995-10-11
HUT72041A (en) 1996-03-28
CN1095263A (en) 1994-11-23

Similar Documents

Publication Publication Date Title
US5358705A (en) Use of N-acetylated amino acid complexes in oral care compositions
WO1994014407A1 (en) Oral compositions containing antiplaque, anticalculus agents
WO1994014406A1 (en) Oral compositions containing antiplaque, anticalculus agents
US5281410A (en) Methods of reducing plaque and gingivitis with reduced staining
US5004597A (en) Oral compositions comprising stannous flouride and stannous gluconate
US5213790A (en) Methods of reducing plaque and gingivitis with reduced staining
EP0162574B1 (en) Oral hygiene compositions
US5145666A (en) Methods of reducing plaque and gingivitis with reduced staining
US5455024A (en) Dentifrices containing zinc oxide particles and sodium bicarbonate
AU2007269423B2 (en) High fluoride ion oral care composition and method for maintaining anticaries activity
CA2140874C (en) Oral compositions
US5578295A (en) Oral care compositions comprising certain substituted diphenyl ethers
JPH09503506A (en) Oral composition
EP0311260B1 (en) Oral compositions
US5500206A (en) Oral compositions comprising actinomyces viscosus fimbriae
GB2210264A (en) Antigingival/antiplaque compositions
EP0311259A2 (en) Oral compositions
US5500208A (en) Oral compositions comprising a novel tripeptide
WO1993018741A1 (en) Oral care compositions comprising certain substituted diphenyl ethers
WO1995033764A1 (en) Oral compositions comprising a novel tripeptide
GB2319726A (en) Polymyxin A, B, C, D or E containing compositions for the treatment of periodontal disease, plaque and breath malodor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR BY CA CZ FI HU JP KP KR KZ LK LV MG MN MW NO NZ PL RO RU SD SK UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1994903459

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2151913

Country of ref document: CA

Ref document number: PV1995-1567

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1994903459

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1995-1567

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1994903459

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1995-1567

Country of ref document: CZ